MedPath

Safety and Efficacy of Longan and Lingzhi Mushroom Syrup on Immune and Inflammatory Responses in Healthy Volunteers

Not Applicable
Completed
Conditions
Safety Issues
Interventions
Dietary Supplement: Longan and lingzhi mushroom syrup
Registration Number
NCT04728009
Lead Sponsor
Chulalongkorn University
Brief Summary

This study aimed to preliminarily determine safety and efficacy of longan and lingzhi mushroom syrup on immune and inflammatory responses. Apparently healthy Thai adults (N = 8) aged 18-60 years were recruited into a prospective, single-group study. All participants were assigned to consume 5 mL of longan and lingzhi mushroom syrup daily for 12 weeks. Blood concentrations of fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), BUN (blood urea nitrogen), creatinine (Cr), immunoglobulins (IgG, IgM, IgA, and IgE), and C-reactive protein (CRP) were measured at baseline (week 0), week 4, week 8, and week 12.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
8
Inclusion Criteria
  1. Apparently healthy adults at Mae Fah Luang University and Chulalongkorn University
  2. aged 18-60 years
  3. HbA1c < 7%
Exclusion Criteria
  1. self-reported immunodeficiency diseases, autoimmune diseases, infectious diseases, diabetes, thyroid diseases, cancer, hepatic- and/or renal dysfunction, uncontrollable illnesses and life-threatening diseases
  2. being allergic to longan and lingzhi products
  3. taking medications, herbs, and diet supplements affecting immune system, inflammatory response, and blood glucose a month before study enrollment
  4. pregnant and breastfeeding women

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
longan and lingzhi mushroom syrupLongan and lingzhi mushroom syrupAll participants (N = 8) were asked to consume 5 mL of longan and lingzhi mushroom syrup as a sweetener daily for 12 weeks.
Primary Outcome Measures
NameTimeMethod
Adverse effects on long-term glycemic control12 weeks

Blood concentrations of HbA1C (in %) were measured.

Adverse effects on renal function (1)12 weeks

Blood concentrations of blood urea nitrogen (in mg/dL) were measured.

Adverse effects on fasting blood glucose12 weeks

Blood concentrations of fasting blood glucose (in mg/dL) were measured.

Adverse effects on hepatic function (1)12 weeks

Blood concentrations of aspatate aminotransferase (AST) (in units/L) were measured.

Adverse effects on hepatic function (3)12 weeks

Blood concentrations of alkaline phosphatase (ALP) (in units/L) were measured.

Adverse effects on hepatic function (2)12 weeks

Blood concentrations of alanine aminotransferase (ALT) (in units/L) were measured.

Adverse effects on renal function (2)12 weeks

Blood concentrations of serum creatinine (in mg/dL) were measured.

Secondary Outcome Measures
NameTimeMethod
Effect on immune responses (3)12 weeks

Blood concentrations of Ig A (in mg/dL) were measured.

Effect on immune responses (1)12 weeks

Blood concentrations of immunoglobulin (Ig) G (in mg/dL) were measured.

Effect on immune responses (2)12 weeks

Blood concentrations of Ig M (in mg/dL) were measured.

Effect on immune responses (4)12 weeks

Blood concentrations of Ig E (in IU/mL) were measured.

Effect on inflammatory responses12 weeks

Blood concentrations of C-reactive protein (in mg/L) were measured.

Trial Locations

Locations (1)

Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn Unviersity

🇹🇭

Bangkok, Thailand

© Copyright 2025. All Rights Reserved by MedPath